(0.31%) 5 115.97 points
(0.31%) 38 359 points
(0.35%) 15 983 points
(-0.86%) $83.13
(5.77%) $2.03
(0.37%) $2 355.80
(0.48%) $27.67
(4.01%) $959.10
(-0.22%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States...
Stats | |
---|---|
本日の出来高 | 168 810 |
平均出来高 | 237 899 |
時価総額 | 90.55M |
EPS | $0 ( 2024-03-05 ) |
次の収益日 | ( $-0.0600 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -18.09 |
ATR14 | $0.0220 (1.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Brown Scott B. | Buy | 224 800 | Employee Stock Option (Right to Buy) |
2023-04-20 | Brown Scott B. | Buy | 3 500 | Common Stock |
2024-03-12 | Theuer Charles | Buy | 518 300 | Employee Stock Option (Right to Buy) |
2023-10-20 | Theuer Charles | Buy | 3 500 | Common Stock |
2023-04-20 | Theuer Charles | Buy | 3 500 | Common Stock |
INSIDER POWER |
---|
80.87 |
Last 100 transactions |
Buy: 3 843 498 | Sell: 406 947 |
ボリューム 相関
TRACON Pharmaceuticals 相関 - 通貨/商品
TRACON Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $12.05M |
総利益: | $12.03M (99.88 %) |
EPS: | $-0.110 |
FY | 2023 |
収益: | $12.05M |
総利益: | $12.03M (99.88 %) |
EPS: | $-0.110 |
FY | 2022 |
収益: | $0 |
総利益: | $-16 000.00 (0.00 %) |
EPS: | $-1.400 |
FY | 2021 |
収益: | $346 000 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.660 |
Financial Reports:
No articles found.
TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。